Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
PET Clin. 2023 Jul;18(3):381-388. doi: 10.1016/j.cpet.2023.02.004. Epub 2023 Mar 27.
Tissue injury in nonmalignant human disease can develop from either disproportionate inflammation or exaggerated fibrotic responses. The molecular and cellular fundamental of these 2 processes, their impact on disease prognosis and the treatment concept deviates fundamentally. Consequently, the synchronous assessment and quantification of these 2 processes in vivo is extremely desirable. Although noninvasive molecular techniques such as F-fluorodeoxyglucose PET offer insights into the degree of inflammatory activity, the assessment of the molecular dynamics of fibrosis remains challenging. The Ga-fibroblast activation protein inhibitor-46 may improve noninvasive clinical diagnostic performance in patients with both fibroinflammatory pathology and long-term CT-abnormalities after severe COVID-19.
非恶性人类疾病中的组织损伤可能由炎症不成比例或纤维化反应过度引起。这两个过程的分子和细胞基础、对疾病预后的影响以及治疗概念有根本的不同。因此，非常希望在体内同步评估和量化这两个过程。虽然 F-氟脱氧葡萄糖 PET 等非侵入性分子技术可深入了解炎症活动程度，但纤维化的分子动力学评估仍具有挑战性。镓-成纤维细胞激活蛋白抑制剂-46 可能会改善严重 COVID-19 后具有纤维化炎症性病理和长期 CT 异常患者的非侵入性临床诊断性能。
